Eversense, the first implantable continuous glucose monitor (CGM), is set to be marketed and sold by Ascensia Diabetes Care starting in late 2020. This comes after Senseonics, the manufacturer of Eversense, faced financial difficulties due to the COVID-19 pandemic. Ascensia, a well-known name in diabetes care, has entered into an agreement with Senseonics to distribute Eversense products globally for at least the next five years. The current Eversense sensor is approved for 90 days of use, but a 180-day version is expected to be submitted for FDA approval soon. Ascensia will also help develop and market a future 365-day sensor. This partnership aims to bring these advanced diabetes management tools to more people, providing them with more options for continuous glucose monitoring.